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RNA splicingThe pathological role of mutations that affect not conserved splicing regulatory sequences can be difﬁcult to
determine. In a patient with Fanconi anemia, we identiﬁed two unpredictable splicing mutations that act on
either sides of FANCA exon 8. In patients-derived cells and in minigene splicing assay, we showed that both an
apparently benign intronic c.710-5TNC transition and the nonsense c.790CNT substitution induce almost
complete exon 8 skipping. Site-directed mutagenesis experiments indicated that the c.710-5TNC transition
affects a polypyrimidine tract where most of the thymidines cannot be compensated by cytidines. The c.790CNT
mutation located in position −3 relative to the donor site induce exon 8 skipping in an NMD-independent
manner and complementation experiments with modiﬁed U1 snRNAs showed that U1 snRNP is only partially
involved in the splicing defect. Our results highlight the importance of performing splicing functional assay for
correct identiﬁcation of disease-causing mechanism of genomic variants and provide mechanistic insights on
how these two FANCAmutations affect exon 8 deﬁnition.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Fanconi anemia (FA) is an autosomal recessive and X-linked disease
characterized by congenital malformations, pancytopenia, and predis-
position to neoplasia, mainly leukemias and head and neck squamous
cell carcinomas. FA cells show chromosomal instability and sensitivity
to DNA interstrand cross-linking agents, such as diepoxybutane or
mitomycin C [1]. FA is a genetically heterogeneous disease caused
by at least 16 genes and the most frequent three (FANCA, FANCC, and
FANCG) account for 80% of the patients [1]. FA represents a challenge in
molecular diagnosis not only for its genetic heterogeneity but also for
the presence of a wide spectrum of mutations, mainly private, whose
disease-causing effect is difﬁcult to determine. Defects in pre-mRNA
splicing represent a signiﬁcant amount of disease causing mutations
but it is not always obvious to establish a direct link between potential
splicing mutations and disease. Most of the difﬁculty is related to the in-
trinsic complexity of the process and the presence of largely degeneratedy; PTC, premature termination
U2AF, U2 auxiliary factor; HSF,
International Centre for Genetic
rieste, Italy. Tel.: +39 040 375consensus splicing sequences. Splicing is performed by the nuclear
spliceosome that identiﬁes the exon-intron boundaries on pre-mRNAs,
excises the intronic sequences and joins the exons to produce themature
RNA. The precise recognition of the exon requires the canonical 5′ and 3′
splice sites (ss) along with a series of largely degenerated sequences
located in the exon or in the intron that can either inhibit or enhance
exon recognition. These elements, named exonic and intronic splicing
enhancers/silencers, are highly degenerated stretches of 6–9 nucleotides
that assist the process of exon selection and are also important for
alternative splicing regulation [2]. In general, trans-acting RNA-binding
proteins interact with these elements and have a positive or a negative
effect on pre-mRNA splicing [3]. The only completely conserved
sequences for splicing are the AG and GT dinucleotides at the 3′ and
5′ss, respectively. However, the consensus sequences near the invari-
ant GT and AG dinucleotides of the splice sites show a certain degree
of variability. The 5′ss consensus (CAG/GTAAGT) includes also the last
three bases of the exon and four intronic bases downstream the invari-
ant GT. On pre-mRNA, the 5′ss interacts with the U1 snRNP through
complementarity between the 5′ tail of the U1 snRNA, the RNA compo-
nent of the particle, and the consensus on the pre-mRNA. Even if this
event occurs in general in the earliest step of spliceosomal assembly
[4], some exons can be recognized in a U1 independent-manner or
this interaction can occur at a later stage, after the recognition of the
3′ss, as recently reported [5]. Mutations in the different positions of
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of U1 snRNP and accordingly, modiﬁed U1 snRNAs complementary
with the aberrant 5′ss have been used both to demonstrate the
U1-dependence of the exon and to provide novel strategies for splicing
correction [6–10]. Interestingly, the modiﬁed U1 does not need to bind
precisely on the 5′ss aswe have shown for Exon Speciﬁc U1s (ExSpeU1).
ExSpeU1s are modiﬁed U1 particles that bind to downstream intronic
sequences and improve the skipping of an exon caused by different
types of mutations that affect the 5′ss, exonic regulatory elements or
the polypyrimidine tract [6].
On the other side of the exon, the canonical 3′ss include the invariant
AG dinucleotide preceded by a stretch of pyrimidines and a branch
point. U2 snRNA and U2 Auxiliary Factors (U2AF) recognize these
sequences. Very few mutations that affect the polypyrimidine tract
have been described in detail [11–15]. In general, mutations that inter-
rupt the pyrimidine stretch with purines [6,16] or reduce their length
[15] result in leaky splicing but no clear disease-causing mutations
have been described for the less deleterious thymidine to cytidine
substitution. These mutations might affect the binding of trans-acting
splicing factors at the polypyrimidine tract like the splicing factor
U2AF65 [16].
As frequently RNA is not available for direct analysis, different bioin-
formatics programs have been developed to evaluate genomic varia-
tions that affect the consensus sequences of splice sites. In general, for
most mutations there is a good relationship between the score obtained
with this analysis and the splicing defects [17]. However, due to the
complexity of the factors involved in splicing recognition, not all splic-
ing mutations can be clearly identiﬁed with these programs and this is
particularly true for those that are in less conserved positions.
In this study, we have addressed the effect on pre-mRNA splicing of
two unusualmutations that are not predicted by bioinformatics analysis
to induce signiﬁcant exon skipping. In FANCAexon 8,we have identiﬁed
an intronic c.710-5TNC transition in the polypyrimidine tract and the
c.790CNT mutation in position−3 of the 5′ss consensus. Through anal-
ysis of patient RNA and minigene plasmids, we have assessed that both
mutations induce severe FANCA exon 8 skipping. The relative U1-
independent recognition of the exon, demonstrated by co-transfection
of modiﬁed U1 RNAs, might be the critical issue that shifts the apparent
mild nature of the mutations toward a severe splicing defect.
2. Materials and Methods
2.1. DNA extraction from lymphoblastoid cell lines of patient
The genomic DNA of FANCA (accession number NM_000135.2) was
isolated from lymphoblastoid cell lines using 5 ml of lysis buffer (Tris–
HCl 10 mM pH 7.5, EDTA 10 mM pH 8, 10 mM NaCl and SDS 0.6 %)
with 1 mg/ml of proteinase K (20 mg/ml). The DNA precipitation was
performed by adding 5 ml of a solution NaCl 75 mM in ethanol 100%.
After centrifugation at 13000 rpm for 10 min, the DNA was washed
with ethanol 100% and left to dry at room temperature before its resus-
pension in DNase free water.
2.2. Mutational screening of FANCA
Exon 8 of the FANCA gene with its ﬂaking regions was ampliﬁed
from genomic DNA using primers 8 F (5′-TGAAGTGGATGGTCTGTGCC-
3′) and 8R (5′-ACACTTGGAATAAGGACGGCT-3′). Ampliﬁcation reaction
was carried out in a ﬁnal volume of 25 μl containing 80 ng of DNA, 12.5
μl of KAPA2G Fast HotStart ReadyMix (KAPABIOSYSTEMS, Resnova) and
1.25 μl of a 10 pM solution of each primer. Initial denaturation was for
2 minutes at 95 °C, followed by 30 cycles, each with denaturation for
10 sec at 95 °C, annealing for 15 sec at 62 °C, and extension for 3 sec
at 72 °C, and a ﬁnal step at 72 °C for 1 min. The ampliﬁed product was
used for direct sequencingusing the BigDyeTerminator Cycle Sequencingkit followed by electrophoresis in an ABI 3100 automated sequencer
(Applied Biosystems).2.3. Evaluation of the splicing pattern of lymphoblastoid cell lines
Total RNAwas prepared from lymphoblastoid cell lines using TRIzol®
(Invitrogen) and cDNA was synthesized with “Transcriptor First Strand
cDNA Synthesis Kit” (Roche). The ampliﬁcation reactionwas performed
using FANCA primers 7 F (5′-GACATGCATGCTGTGGGATC-3′) and 10R
(5′-GCACCTCACGATCTTGTGAG-3′). RT-PCR and sequencing analysis
were carried out as above.2.4. Splicing assay with hybrid minigenes
HeLa cells were grown in Dulbecco's modiﬁed Eagle's mediumwith
Glutamax I (Gibco) supplementedwith 10% fetal calf serum (EuroClone)
and antibiotic antimycotic (Sigma). HeLa cells were transfected with
Effectene reagent (Qiagen) with 500 ng of each minigene plasmid [18].
In co-transfection experiments 500 ng of the plasmid were transfected
with 500 ng of the U1 minigene. Total RNA extraction was performed
24 h after transfection using TriReagent (Invitrogen); RT–PCR and quan-
titation of the intensity of the ampliﬁed products in agarose gels using
ImageJ softwarewere done as previously described [18]. For the analysis
of the splicing isoforms the primers alfa2,3 (5′-CAACTTCAAGCTCCTAAG
CCACTGC-3′) and pFAN_904 rev (5′-ATCAGCATTCTCTGAAGTACATCA
AC-3′) were used.2.5. Plasmid construction
A905 bp cassette that contains FANCA exons 7 and 9with portions of
intron 7 and intron 8 was ordered from GeneScript and cloned in the
BstEII site of the third exon of theα-globinminigene [19] under the con-
trol of theα-globin promoter and the SV40 enhancer. A unique NdeI site
was inserted between intron 7 and intron 8. The entire 82 bp ex8 with
portions of the ﬂanking intron 7 and 8 was ampliﬁed from wt and mu-
tated genomic DNA using the primers Fan_1_PstI dir (5′-ATCATATGCT
GCAGCACCCGCCCCTCTGAAGTGGATG-3′) and Fan_400_EcoRV rev (5′-
ATCATATGAATTCGCCAACACACAGAAATGATACAT-3′) and cloned in
theNdeI site.Mutantminigenes of the polypyrimidine tractwere created
through overlapping PCR. Modiﬁed U1 snRNAs and ExSpeU1 plasmids
were created by replacing the sequence between the sites BclI and BglII
of the wt gene with oligonucleotides as previously reported [20].2.6. siRNA
siRNA transfections were performed in HeLa cells using Oligofectamine
reagent (Invitrogen) according tomanifacturer's instructions. The sense
strands of RNA interference oligonucleotides (Dharmacon) used for
silencing human hnRNPA1 is 5′-CAGCUGAGGAAGCUCUUCA-3′, for
hnRNPA2 is 5′-GGAACAGUUCCGUAAGCUC-3′ and for the control oligo-
nucleotide (siLuc) is 5′-GCCAUUCUAUCCUCUAGAGGAUG-3′. siRNA
was performed as previously described [19].2.7. Western Blot
Proteins were loaded on a 12% SDS-PAGE gel and electroblotted on a
polyvinylidene diﬂuoride membrane according to standard protocols
(Amersham Biosciences). The membrane was blocked with phosphate-
buffered saline-5% skimmed milk. hnRNPA1/A2 was identiﬁed using
rabbit anti-hnRNPA1/A2 1:1000 (kindly provided by R. Klima). Western
blot signal was detected with ECL (Pierce Biotechnology).
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3.1. Identiﬁcation of the c.710-5TNC and c.790CNT mutations and RNA
analysis in lymphoblastoid cell line
The screening of the FANCA gene in one FA family identiﬁed two
mutations, c.710-5TNC and c.790CNT, in heterozygosis. c.710-5TNC is
located in the polypyrimidine tract of exon 8 whereas c.790CNT is in
the terminal portion of the exon, three bases upstream of the 5′ss (po-
sition −3 relative to the donor site) (Fig. 1a). The polypyrimidine
tract c.710-5TNC substitution was found in linkage disequilibrium
with a nearby upstream SNP rs1800286 (c.710-12GNA). The two affect-
ed individuals had theGCC paternal and ATTmaternal haplotypeswhile
the healthy sister carried the maternal mutant haplotype and the non-
deleterious paternal one (Fig. 1b). To test the effect of the twomutations
on pre-mRNA splicing, we directly analysed themRNA extracted from a
lymphoblastoid cell line derived from the affected individual II-1 with
primers located on exons 7 and 10. The RT-PCR analysis of the patient
showed only FANCA transcripts without exon 8 (product of 205 bp in
Fig. 1c), while a band of 288 bp, corresponding to exon 8 inclusion,
was the result of the same analysis on RNA from control individuals
(band of 288 bp in Fig. 1c, lanes C1 and C2). This result suggests that
the two mutations directly affect pre-mRNA splicing and the deﬁnition
of exon 8. Exon 8 skipping (r.710_792del) results in a frameshift muta-
tion (p.Asp237Glyfs*4).
3.2. Exon 8 skipping induced by c.790CNT is not due to nonsense-mediated
decay
Since the c.790CNTmutation creates a premature termination codon
(PTC) in exon 8, we investigated if the absence of exon 8 in the mature
transcript might be due to its degradation through nonsense-mediated
decay (NMD) [21]. Although current models predict that a PTC elicits
mRNA degradation only if located more than 50 bp from the exon/Fig. 1. Identiﬁcation of FANCA variants in the FA family. (a) Position of SNP c.710-12ANG (rs18
with haplotype construction at the three loci. (c) RT-PCR analysis on total RNA from lymphoblas
as in controls C1 and C2 results in the skipping of exon 8. (d) Sequencing analysis of the mutan
similar levels.exon junction, there are notable exceptions [22]. To rule out a contribu-
tion of this mechanism, we performed experiments to be sure that exon
skipping was complete in vivo. To this end, we took advantage of a
heterozygous nucleotide change (rs7190823 SNP) present in exon 9 to
determine the relative expression levels of the two alleles. Sequence
analysis of the transcripts derived from ampliﬁcation of the lympho-
blasts of the II-1 patient showed that the two “A” and “G” peaks at the
polymorphic locuswere similarly represented, excluding any signiﬁcant
degradation of one of the two mutant FANCA allele-derived transcripts
(Fig. 1d). As the c.790CNT variation is relatively common in the Italian
population [23], we analysed the RNA from another patient, heterozy-
gous for the samemutation, conﬁrming the presence of exon 8 skipping
(data not shown).
3.3. The c.710-5TNC and c.790CNT mutations induce exon skipping in the
pFAN minigene
In order to determine more in detail the contribution of the c.710-
5TNC and c.790CNT substitutions on pre-mRNA splicing, we prepared a
pFAN hybrid minigene, that contains FANCA exons 7 and 9, portions
of the corresponding introns and different variants of exon 8 in the
context of the beta globin minigene [18] (Fig. 2). Minigenes were
transiently transfected in HeLa cells, and the pattern of splicing
analysed by RT-PCR ampliﬁcation with speciﬁc primers. Transfection
experiments showed two isoforms of 261 bp and 176 bp that corre-
spond to transcripts that include or exclude exon 8, respectively. The
two normal ATC and GTC haplotypes, that differ at the -12ANG SNP in
the polypyrimidine tract, showed mainly normal processing with
~80% of transcripts that include exon 8 (Fig. 2). On the contrary, analysis
of the proband haplotypes showed complete disruption of exon 8 splic-
ing. In fact, both the c.710-5TNC mutant of the polypyrimidine tract
(haplotype GCC in Fig. 2), and mutation on the exon c.790CNT (haplo-
type ATT, Fig. 2) showed only the exon 8 skipping isoform. These results
indicate that both the c.710-5TNC at the polypyrimidine tract and the00286) and mutations c.710-5TNC and c.790CNT in relation to exon 8. (b) Family pedigree
toid cell line established fromproband II-1. The unique product of 205 bp instead of 288 bp
t 205 bp product showing the “A” and “G” alleles of SNP rs7190823 in exon 9 expressed at
Fig. 2. The GCC and ATT haplotypes severely impair FANCA exon 8 splicing pattern in minigene system. Schematic representation and sequence of pFAN ex8 minigene and the different
haplotypes analyzed. Boxes represent exons and thin lines are introns. Arrows indicate the primers used for the PCR analysis. Mutated nucleotides are indicated in bold. The lower panel
shows the splicing proﬁle of the different pFAN ex8 constructs after transfection in HeLa cells. Band identity is indicated on the right. Numbers below the ﬁgure are percentages of exon8
inclusion indicated as mean±st.dev of at least three independent experiments. M: marker.
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while the -12ANG polymorphism has no effect on RNA processing.
3.4. The stretch of thymidines in the polypyrimidine tract is required for
efﬁcient acceptor splice site recognition
As the polypyrimidine tract normally contains a mixture of T and C
nucleotides, we decided to better investigate why the c.710-5 TNC
transversion has a deleterious effect on FANCA exon 8 deﬁnition. Bioin-
formatics analysis of the 3′ss strength performed with neural networks
(NNSPLICE 0.9) showed that the TNC transition has a modest impact on
the 3′ss score (from 91 to 84) (Fig. 3) indicating the difﬁculty in
predicting the effect of the mutation on splicing. The scores obtainedFig. 3. The TNC transition in the polypyrimidine tract is detrimental for splicing of FANCA exon
mutations in the polypyrimidine tract. On the right, the splice site strength of each mutant is
each minigene after transfection in HeLa cells. GTC refers to the wild-type minigene. Band id
mean±st.dev of at least three independent experiments. M: marker.with the Human Splicing Finder (HSF) predictor program were even
less severe (data not shown). To investigate the importance of the
polypyrimidine tract in exon 8 deﬁnition, we mutated the four thymi-
dines from position −5 to −8 either in the conservative C or the
most disruptive G (Fig. 3). We transfected the minigenes in HeLa cells
(Fig. 3) and after RT-PCR analysis, we observed that the substitutions
in the more proximal positions to the 3′ss (−5 and−6) induced com-
plete exon skipping (Fig. 3). The -7C and, to a minor extent, the -7G and
-8C maintained some normal splicing activity (Fig. 3) whereas the -8G
showed complete exon skipping. These experiments demonstrate that
FANCA exon 8 splicing does not tolerate sequence changes at the
polypyrimidine tract, even the conservative T to C transitions. Interest-
ingly, there was no correlation between the bioinformatics prediction8. Nucleotide sequence of intron 7 (lower cases) and exon 8 (upper cases) showing the
indicated, as calculated with NNSPLICE 0.9. The lower panel shows the splicing proﬁle of
entity is depicted on the right. Numbers below the panel indicate splicing efﬁciency as
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showed only a moderate reduction of the 3′ss score.
3.5. Effect of the c.790CNT mutation on the 5′ss recognition mediated by U1
snRNPs
The exonic c.790CNTmutation occurs at the relatively conserved C in
position−3 of the donor site but only minimally reduces its score, as
determined with different programs (from 93 to 75 with NNSPLICE
0.9, from 89 to 74 with the HSF and from 9.72 to 7.00 with the
MaxEntScan). To understand the effect of the mutation on 5′ss function
we performed experiments with modiﬁed U1 snRNPs. In different
genes, several disease-causing substitutions at the donor site can be res-
cued using U1 snRNPs engineered to bind by complementarity to the
mutated 5′ss or to downstream sequences [6]. The 5′ tail of the wild
type U1 snRNA lacks sequence complementarity with the c.790CNT 5′
ss in three positions: the mutant -3 T, and the downstream natural
nucleotides +4G and +6A (Fig. 4a). Therefore, we created two U1
snRNA variants: U1+4G+6A and U1-3T+4G+6A complementary to
the wild type and to the c.790-3CNT mutant, respectively. The modiﬁed
U1 snRNAs were transfected along with the ATT minigene and the
pattern of splicing evaluated by RT-PCR. As shown in Fig. 4a, the non-
modiﬁed U1 (U1 wt in Fig. 4a) and the U1+4G+6A, complementary
to the wild type exon 8, did not alter the pattern of splicing of the ATT
minigene. On the contrary, the U1-3T+4G+6A complementary to the
mutated donor site increased the splicing efﬁciency to ~20% (Fig. 4a).
In parallel, we evaluated the ability of ExSpeU1s in correcting theFig. 4.U1snRNPpartially rescue theATT haplotype. (a) Schematic representation of the 5′ss of F
Splicing pattern of theATTminigene after co-transfection inHeLa cells of U1 snRNPparticles com
portions of intron 8 (ExSpU1 3–10, 10–16 and 10–27). Band identity is shown on the right. The
indicated below the panel. (b) Splicing pattern of the ATT minigene after co-transfection in HeL
absence (−) of siRNA directed against hnRNPA1/A2. Band identity is shown on the right. The p
indicated below the panel. M: marker. The bottom part of panel (b) is a representative wester
imental conditions: non-treated cells, cells with a mock siRNA (siLuc), cells with siRNA againstskipping of exon 8. We tested three different ExSpeU1s designed to
bind to nucleotides in positions 3–10, 10–16 and 10–27 downstream
of the donor site. Co-transfection in HeLa cells of ExSpeU1 3–10 had
no effect on the splicing pattern of the ATT minigene (Fig. 4a), while
the inclusion of exon 8 was partially restored by ExSpeU1 10–16 and
ExSpeU1 10–27 (~10% and ~20% of exon 8 inclusion, respectively)
(Fig. 4a). These results suggest that the c. 790CNT mutation partially
affects the U1 snRNP binding to the 5′ss.
Exonic mutations associated to exon skipping can also create Exonic
Splicing Silencers bound by hnRNPA1/A2 [24] and sequence inspection
of the c. 790CNT mutation showed that it creates a perfect consensus
binding site for the these proteins (TAGGTAG). To understand the con-
tribution of this splicing factor, we evaluated the effect of hnRNPA1/A2
silencing on the splicing pattern in the presence or absence of modiﬁed
U1 complementary to the mutant 5′ss (Fig. 4b). In pFAN ex8 ATT,
hnRNPA1/A2 silencing alone slightly increases the percentage of exon
inclusion (from 0 to 5%). Similarly, hnRNPA1/A2 silencing along with
co-transfection of U1-3T+4G+6A alone slightly increases the percent-
age of exon inclusion (from 20 to 30%). Thus, U1 snRNP and hnRNPA1/
A2 only in part contribute to the inhibitory effect of the mutation on
splicing.
4. Discussion
The effect of genomic variants on gene expression is not always easy
to predict, as it is the case of themutations we have identiﬁed in the FA
patient reported in this paper. At ﬁrst, the c.710-5TNC transition wasANCA exon8 and of theposition of themodiﬁedU1 snRNAs used to rescue exon8 inclusion.
plementary to the 5′ss (U1+4G+6A andU1-3T+4G+6A) or ExSpeU1 complementary to
percentage of exon inclusion asmean±st.dev of at least three independent experiments is
a cells of U1 snRNPs complementary to the 5′ss (U1-3 T+4G+6A) in the presence (+) or
ercentage of exon inclusion as mean±st.dev of at least three independent experiments is
n blot performed against hnRNPA1/A2 and tubulin as a loading control in different exper-
hnRNPA1/A2 and HeLa nuclear extract (NE).
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polypyrimidine sequences upstream of the acceptor site contain a mix-
ture of T and C nucleotides, this mutation only minimally reduced the
splice site score of the 3′ss (from 91 to 84, calculated with NNSPLICE
0.9). Similarly, the c.790CNT change in the last portion of exon 8 was
predicted to be a nonsensemutationwithout any effect on RNAprocess-
ing. Furthermore, affecting the non-conserved position−3 of the donor
site did not cause a signiﬁcant change in the score of the 5′ss. In spite of
this evidence, we show that both in patients' derived cells and in
minigenes, the two mutations cause FA by affecting pre-mRNA splicing
through a mechanism that induces complete skipping of exon 8 from
the mature transcripts.
The number of polypyrimidine tract mutations reported and evalu-
ated for their effect on splicing is limited.Most of themare transversions
or mutations that reduce the number of thymidines [6,11,12,14,15]. To
our knowledge, this is the ﬁrst clearly described disease-causing
polypyrimidine tract T to C mutation. In order to understand why the
apparent benign c.710-5TNC transition induces complete exon 8 skip-
ping, we evaluated in minigene experiments point TNC and TNG substi-
tutions in the polyprimidine tract fromposition−5 to−8. Both C andG
substitutions at positions−5 and−6 and to a less extent at positions
−7 and −8 severely affected recognition of the 3′ss, indicating that
thymidines are necessary for FANCA exon 8 splicing. The relatively
short length of the polypyrimidine tract (ﬁve T) might be the critical
determinant for FANCA exon 8 deﬁnition and explain why this tract
cannot tolerate even the less deleterious transitions. Using model
viral systems, earliest in vitro studies showed that the length of the
polypyrimidine tract [25,26], the total number of T relative to other
nucleotides [27,28] and the strength of the branch point [25] are impor-
tant for splicing. Indeed, the length of the polymorphic polypyrimidine
tract has been shown to regulate splicing of CFTR exon 9 and in vivo the
shorter allele with ﬁve T is associated to monosymptomatic forms of
cystic ﬁbrosis and lower percentage of exon inclusion [29]. However,
in CFTR the presence of an upstream TG repeat bound by the inhibitory
splicing factor TDP-43 is the major contributor to the splicing outcome,
highlighting the importance of the context where the polypyrimidine
tracts are embedded.Mutations in the polypyrimidine tract are expected
to interfere with the assembly of the U2 snRNP complex, including
U2AF65 andU2AF35 that are important for the 3′ss recognition. Recently,
a more disruptive mutation (T to G) in the polypyrimidine tract of the
GAA gene exon 2, associated to lysosomal alpha-glucosidase deﬁciency,
was shown to abrogate the binding of U2AF65 [16].
On the other hand, the c.790CNT change is located at the end of exon
8 in position−3 of the donor site and in commonwith similar substitu-
tions, its pathological effect was mainly considered due to the genera-
tion of a stop codon, leading to a truncated, non-functional FANCA
protein. In this paper, we show that unexpectedly, the disease-causing
effect of the mutation is severe exon skipping. We also exclude that
the absence of exon 8 in the mature transcript is due to NMD. The
accurate identiﬁcation of the molecular defect is critical for the
development of correct therapeutic strategies and in this case the
usage of stop-codon read-through drugs [30–32] is not expected to
work without a previous correction of exon skipping. Even if the−3
position of the 5′ss is not strictly required for 5′ss function, the CNTmu-
tation disrupts the complementarity with U1 snRNA. To test the role of
U1 snRNP, we performed co-transfection experiments with modiﬁed
U1 snRNAs either complementary to themutated 5′ss or to downstream
intronic regions (ExSpeU1s). These two U1 snRNAs were shown to cor-
rect exon skipping in several gene systems. [6–10] Unexpectedly, the
modest effect of U1 and ExSpeU1s in rescuing exon skipping of the
c.790CNT mutation (Fig. 4a) suggests that either U1 snRNP might not
be strictly required for FANCA exon 8 deﬁnition, as previously proposed
for exon 10 of the humanmithocondrial ATP synthase [33] and for exon
29 of neuroﬁbromatosis type 1 [34], or the creation of a silencer. In the
latter case, binding of inhibitory splicing factors(s) might compete
with the U1 on the 5′ss. Indeed, the mutation creates a sequencecomplementary to the consensus hnRNPA1/A2 site, but silencing
experiments showed a negligible role of this factor in rescuing splicing
(Fig. 4b). It is possible that binding of additional inhibitory splicing
factors contributes to the complete exclusion of the exon from the
mature transcript as other predicted silencer motifs may indeed be
generated by the mutation [35].
Understanding the pathological effect of mutations on gene expres-
sion is important not only for unravelling the molecular mechanisms
but also for providing insights into potential strategies to restore the
functional activity of the mutated gene. As discussed, splicing rescue
of the c.790CNT nonsense mutation should be associated with stop-
codon read-through drugs [30–32]. Complete or even partial splicing
rescue in the FANCA gene associated to the intronic polypyrimidine
tract mutation could restore sufﬁcient protein expression level and pre-
vent manifestations of pathological phenotype. Recently, some drugs
have been shown to correct splicing defects caused by polypyrimidine
tract mutation in lysosomal alpha-glucosidase deﬁciency [16] and
future studies will try to identify similar active compounds in FANCA.
Acknowledgments
This work was supported by grants: 1610 from AFM-Telethon (to
FP), 10387 from Associazione Italiana per la Ricerca sul Cancro (AIRC)
(to FP), GGP11076 from Telethon Foundation (to AS), 36/07 from
IRCCSBurlo Garofolo (toAS), AIRFA (ItalianAssociation for Fanconi Ane-
mia Research) (to AS). The samples were obtained from the “Cell Line
andDNABiobank fromPatients affected byGenetic Diseases” (G. Gaslini
Institute) - Telethon Genetic Biobank Network (Project No. GTB07001).
We thank Andrea Dal Mas for the siRNA experiments.
References
[1] H. Joenje, K.J. Patel, The emerging genetic and molecular basis of Fanconi anaemia,
Nat. Rev. Genet. 2 (2001) 446–457.
[2] M. Chen, J.L. Manley, Mechanisms of alternative splicing regulation: insights from
molecular and genomics approaches, Nat. Rev. Mol. Cell Biol. 10 (2009) 741–754.
[3] J.F. Caceres, A.R. Kornblihtt, Alternative splicing: multiple control mechanisms and
involvement in human disease, Trends Genet. 18 (2002) 186–193.
[4] M.C. Wahl, C.L. Will, R. Luhrmann, The spliceosome: design principles of a dynamic
RNP machine, Cell 136 (2009) 701–718.
[5] I. Shcherbakova, A.A. Hoskins, L.J. Friedman, V. Serebrov, I.R. Correa Jr., M.Q. Xu, J.
Gelles, M.J. Moore, Alternative spliceosome assembly pathways revealed by
single-molecule ﬂuorescence microscopy, Cell Rep. 5 (2013) 151–165.
[6] E. Fernandez Alanis, M. Pinotti, A. Dal Mas, D. Balestra, N. Cavallari, M.E. Rogalska, F.
Bernardi, F. Pagani, An exon-speciﬁc U1 small nuclear RNA (snRNA) strategy to
correct splicing defects, Hum. Mol. Genet. 21 (2012) 2389–2398.
[7] M. Baralle, D. Baralle, L. De Conti, C. Mattocks, J. Whittaker, A. Knezevich, C. Ffrench-
Constant, F.E. Baralle, Identiﬁcation of a mutation that perturbs NF1 agene splicing
using genomic DNA samples and a minigene assay, J. Med. Genet. 40 (2003)
220–222.
[8] M. Pinotti, D. Balestra, L. Rizzotto, I. Maestri, F. Pagani, F. Bernardi, Rescue of coagu-
lation factor VII function by the U1+5A snRNA, Blood 113 (2009) 6461–6464.
[9] L. Susani, A. Pangrazio, C. Sobacchi, A. Taranta, G. Mortier, R. Savarirayan, A. Villa, P.
Orchard, P. Vezzoni, A. Albertini, A. Frattini, F. Pagani, TCIRG1-dependent recessive
osteopetrosis: mutation analysis, functional identiﬁcation of the splicing defects,
and in vitro rescue by U1 snRNA, Hum. Mutat. 24 (2004) 225–235.
[10] G. Tanner, E. Glaus, D. Barthelmes, M. Ader, J. Fleischhauer, F. Pagani, W. Berger, J.
Neidhardt, Therapeutic strategy to rescue mutation-induced exon skipping in
rhodopsin by adaptation of U1 snRNA, Hum. Mutat. 30 (2009) 255–263.
[11] M.L. Huie, A.S. Chen, S. Tsujino, S. Shanske, S. DiMauro, A.G. Engel, R. Hirschhorn,
Aberrant splicing in adult onset glycogen storage disease type II (GSDII): molecular
identiﬁcation of an IVS1 (−13 T–NG)mutation in a majority of patients and a novel
IVS10 (+1GT–NCT) mutation, Hum. Mol. Genet. 3 (1994) 2231–2236.
[12] A. David, F. Miraki-Moud, N.J. Shaw, M.O. Savage, A.J. Clark, L.A. Metherell, Identiﬁ-
cation and characterisation of a novel GHR defect disrupting the polypyrimidine
tract and resulting in GH insensitivity, Eur. J. Endocrinol. 162 (2010) 37–42.
[13] S.H. Lefevre, L. Chauveinc, D. Stoppa-Lyonnet, J. Michon, L. Lumbroso, P. Berthet, D.
Frappaz, B.Dutrillaux, S. Chevillard, B.Malfoy, A T to Cmutation in thepolypyrimidine
tract of the exon 9 splicing site of the RB1 gene responsible for lowpenetrance hered-
itary retinoblastoma, J. Med. Genet. 39 (2002) E21.
[14] P. Sebillon, C. Beldjord, J.C. Kaplan, E. Brody, J. Marie, A T to G mutation in the
polypyrimidine tract of the second intron of the human beta-globin gene reduces
in vitro splicing efﬁciency: evidence for an increased hnRNP C interaction, Nucleic
Acids Res. 23 (1995) 3419–3425.
[15] F. Pagani, E. Buratti, C. Stuani, M. Romano, E. Zuccato,M. Niksic, L. Giglio, D. Faraguna,
F.E. Baralle, Splicing factors induce cystic ﬁbrosis transmembrane regulator exon 9
1058 C. Mattioli et al. / Biochimica et Biophysica Acta 1842 (2014) 1052–1058skipping through a nonevolutionary conserved intronic element, J. Biol. Chem. 275
(2000) 21041–21047.
[16] A. Dardis, I. Zanin, S. Zampieri, C. Stuani, A. Pianta, M. Romanello, F.E. Baralle, B.
Bembi, E. Buratti, Functional characterization of the common c.-32-13 TNGmutation
of GAA gene: identiﬁcation of potential therapeutic agents, Nucleic Acids Res. 42
(2014) 1291–1302.
[17] D. Baralle, M. Baralle, Splicing in action: assessing disease causing sequence changes,
J. Med. Genet. 42 (2005) 737–748.
[18] F. Pagani, C. Stuani, M. Tzetis, E. Kanavakis, A. Efthymiadou, S. Doudounakis, T.
Casals, F.E. Baralle, New type of disease causing mutations: the example of the com-
posite exonic regulatory elements of splicing in CFTR exon 12, Hum. Mol. Genet. 12
(2003) 1111–1120.
[19] T. Pastor, G. Talotti, M.A. Lewandowska, F. Pagani, An Alu-derived intronic splicing
enhancer facilitates intronic processing and modulates aberrant splicing in ATM,
Nucleic Acids Res. 37 (2009) 7258–7267.
[20] F. Pagani, E. Buratti, C. Stuani, R. Bendix, T. Dork, F.E. Baralle, A new type of mutation
causes a splicing defect in ATM, Nat. Genet. 30 (2002) 426–429.
[21] F. Lejeune, L.E. Maquat, Mechanistic links between nonsense-mediatedmRNA decay
and pre-mRNA splicing in mammalian cells, Curr. Opin. Cell Biol. 17 (2005)
309–315.
[22] O. Isken, L.E. Maquat, Quality control of eukaryotic mRNA: safeguarding cells from
abnormal mRNA function, Genes Dev. 21 (2007) 1833–1856.
[23] D. De Rocco, R. Bottega, E. Cappelli, S. Cavani, M. Criscuolo, E. Nicchia, F. Corsolini, C.
Greco, A. Borriello, J. Svahn, M. Pillon, C. Mecucci, G. Casazza, F. Verzegnassi, C.
Cugno, A. Locasciulli, P. Farruggia, D. Longoni, U. Ramenghi, W. Barberi, F. Tucci, S.
Perrotta, P. Grammatico, H. Hanenberg, F. Della Ragione, C. Dufour, A. Savoia, Molec-
ular analysis of Fanconi anemia: the experience of the Bone Marrow Failure Study
Group of the Italian Association of Pediatric Onco-Hematology, Haematologica
(2014) (in press).
[24] E. Goina, N. Skoko, F. Pagani, Binding of DAZAP1 and hnRNPA1/A2 to an exonic splic-
ing silencer in a natural BRCA1 exon 18 mutant, Mol. Cell. Biol. 28 (2008) 3850–
3860.[25] R.F. Roscigno, M. Weiner, M.A. Garcia-Blanco, A mutational analysis of the
polypyrimidine tract of introns. Effects of sequence differences in pyrimidine
tracts on splicing, J. Biol. Chem. 268 (1993) 11222–11229.
[26] C.J. Coolidge, R.J. Seely, J.G. Patton, Functional analysis of the polypyrimidine tract in
pre-mRNA splicing, Nucleic Acids Res. 25 (1997) 888–896.
[27] R. Reed, The organization of 3' splice-site sequences in mammalian introns, Genes
Dev. 3 (1989) 2113–2123.
[28] A.R. Krainer, T. Maniatis, B. Ruskin, M.R. Green, Normal and mutant human
beta-globin pre-mRNAs are faithfully and efﬁciently spliced in vitro, Cell 36 (1984)
993–1005.
[29] F. Pagani, E. Buratti, C. Stuani, F.E. Baralle, Missense, nonsense, and neutral muta-
tions deﬁne juxtaposed regulatory elements of splicing in cystic ﬁbrosis transmem-
brane regulator exon 9, J. Biol. Chem. 278 (2003) 26580–26588.
[30] V. Allamand, L. Bidou, M. Arakawa, C. Floquet, M. Shiozuka, M. Paturneau-Jouas, C.
Gartioux, G.S. Butler-Browne, V. Mouly, J.P. Rousset, R. Matsuda, D. Ikeda, P.
Guicheney, Drug-induced readthrough of premature stop codons leads to the
stabilization of laminin alpha2 chain mRNA in CMD myotubes, J. Gene Med. 10
(2008) 217–224.
[31] V. Malik, L.R. Rodino-Klapac, L. Viollet, J.R. Mendell, Aminoglycoside-induced muta-
tion suppression (stop codon readthrough) as a therapeutic strategy for Duchenne
muscular dystrophy, Ther. Adv. Neurol. Disord. 3 (2010) 379–389.
[32] C. Floquet, J.P. Rousset, L. Bidou, Readthrough of premature termination codons in
the adenomatous polyposis coli gene restores its biological activity in human cancer
cells, PLoS One 6 (2011) e24125.
[33] K. Fukumura, I. Taniguchi, H. Sakamoto, M. Ohno, K. Inoue, U1-independent
pre-mRNA splicing contributes to the regulation of alternative splicing, Nucleic
Acids Res. 37 (2009) 1907–1914.
[34] M. Raponi, E. Buratti, E. Dassie, M. Upadhyaya, D. Baralle, LowU1 snRNP dependence
at the NF1 exon 29 donor splice site, FEBS J. 276 (2009) 2060–2073.
[35] S. Ke, S. Shang, S.M. Kalachikov, I. Morozova, L. Yu, J.J. Russo, J. Ju, L.A. Chasin, Quan-
titative evaluation of all hexamers as exonic splicing elements, Genome Res. 21
(2011) 1360–1374
